NEUROMETRIX, INC. (NASDAQ:NURO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.
announcing its financial results for the quarter ended March 31,
2017. The full text of the press release and the related
attachment are furnished as Exhibit 99.1 hereto and incorporated
herein by reference.
|
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release of NeuroMetrix, Inc. dated April 20,
2017, including attachment. |
About NEUROMETRIX, INC. (NASDAQ:NURO)
NeuroMetrix, Inc. (NeuroMetrix) is a health-care company that develops wearable medical technology and point-of-care tests that help patients and physicians manage chronic pain, nerve diseases and sleep disorders. The Company operates through the sale of medical equipment and consumables segment. Its products are sold in the United States and selected overseas markets. It has two principal product lines: Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The Company’s products consist of a medical device used in conjunction with a consumable electrode or biosensor. Its products include Quell, which is a wearable device for relief of chronic intractable pain; SENSUS, which is a prescription neuro-stimulation device; DPNCheck, which is a nerve conduction test that is used to evaluate systemic neuropathies, and ADVANCE System, which is a platform for the performance of nerve conduction studies. NEUROMETRIX, INC. (NASDAQ:NURO) Recent Trading Information
NEUROMETRIX, INC. (NASDAQ:NURO) closed its last trading session down -0.040 at 0.670 with 1,580,842 shares trading hands.
